{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:27:55Z","timestamp":1793125675385,"version":"4.5.0"},"reference-count":82,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"crossref","award":["847845"],"award-info":[{"award-number":["847845"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To evaluate the diagnostic accuracy and clinical utility of posttreatment tests to predict treatment failure after excisional treatment of cervical intraepithelial neoplasia grade 2 or worse (CIN 2+).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCES:<\/jats:title>\n                    <jats:p>Electronic databases (EMBASE, PubMed MEDLINE) were searched for studies published from January 1975 to August 2024 assessing the occurrence of treatment failure in women who underwent excisional treatment for histologically confirmed CIN 2+ lesion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS OF STUDY SELECTION:<\/jats:title>\n                    <jats:p>Previously published meta-analyses were extended and updated. A total of 1,802 studies were reviewed. Studies that assessed the diagnostic accuracy of the margin status, cytologic testing, combination of cytology and high-risk human papillomavirus (HPV), or combination of margin status and high-risk HPV compared with high-risk HPV testing were included. The primary outcome was treatment failure (residual or recurrent CIN 2+) and the absolute and relative diagnostic accuracy to predict this outcome. Studies with at least 18 months of follow-up were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>TABULATION, INTEGRATION, AND RESULTS:<\/jats:title>\n                    <jats:p>Forty-six studies and 20,385 women were included in the analysis. Treatment failure occurred in 6.6% of patients. The pooled sensitivity and specificity of high-risk HPV testing were 86.8% and 80.5%, respectively. Cytology had a sensitivity of 70.8% and a specificity of 85.7%, pooled from 34 studies. Compared with high-risk HPV testing in the same studies, cytology was 6.5% more specific (95% CI, 1.024\u20131.108) but 21.3% less sensitive (95% CI, 0.702\u20130.882). Assessment of the margin status was 39.9% less sensitive (95% CI, 0.532\u20130.678) but similarly specific (95% CI, 0.970\u20131.069) to high-risk HPV testing in 29 studies, with a pooled sensitivity and specificity of 48.9% and 82.5%, respectively. Co-testing with cytology and high-risk HPV was similarly sensitive (95% CI, 0.992\u20131.061) but 10.5% less specific (95% CI, 0.850\u20130.944) compared with high-risk HPV testing in 16 studies, with a pooled sensitivity and specificity of 94.7% and 69.9%, respectively. The pooled sensitivity and specificity of co-testing with margin status and high-risk HPV were 96.9% and 55.7%, respectively, 6.6% more sensitive (95% CI, 1.021\u20131.114) but 26.7% less specific (95% CI, 0.637\u20130.844) than high-risk HPV testing in eight studies. Involved resection margins, abnormal cytology, and a positive high-risk HPV test result were associated with a failure risk of 16.1%, 29.0%, and 26.1%, respectively. Women with negative margins, normal cytology, and a negative high-risk HPV test result had a failure risk of 3.6%, 2.3%, and 0.9%, respectively. The risk of treatment failure was highest for women with involved margins and a positive high-risk HPV test result (45.3%) and lowest for women with negative margins and a negative high-risk HPV test result (0.3%). Abnormal cytology and a positive high-risk HPV test result increased the risk of treatment failure to 42%, whereas normal cytology and a negative high-risk HPV test result decreased the risk to 0.6%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>High-risk HPV testing is highly sensitive and specific to predict residual or recurrent CIN 2+ after excisional treatment. Cytologic testing and assessment of the margin status are slightly more and similarly specific, respectively, but both are significantly less sensitive. High-risk HPV testing can sufficiently inform the posttreatment management based on the posttest risk of treatment failure, unlike both cytology and assessment of the margin status. High-risk HPV testing alone performs similarly to co-testing with cytology or margin status. Posttreatment high-risk HPV testing is therefore an accurate predictor of treatment failure in women treated for CIN 2+.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000005997","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T21:00:27Z","timestamp":1752181227000},"page":"487-499","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Prediction of Treatment Failure After Excisional Treatment of Cervical Precancer"],"prefix":"10.1097","volume":"146","author":[{"given":"Leandro","family":"Bomans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianis Tatiana","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hillemanns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Gultekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Arbyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"R1-20260825","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1016\/S2214-109X(22)00501-0","article-title":"Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative","volume":"11","author":"Singh","year":"2023","journal-title":"Lancet Glob Health"},{"key":"R2-20260825","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/00004347-199304000-00018","article-title":"Natural history of cervical intraepithelial neoplasia: a critical review","volume":"12","author":"Ost\u00f6r","year":"1993","journal-title":"Int J Gynecol Pathol"},{"key":"R3-20260825","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bpobgyn.2011.04.007","article-title":"Management options for cervical intraepithelial neoplasia","volume":"25","author":"Petry","year":"2011","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"R4-20260825","first-page":"131","article-title":"A modified terminology for cervical intraepithelial neoplasia","volume":"75","author":"Richart","year":"1990","journal-title":"Obstet Gynecol"},{"key":"R5-20260825","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(08)70103-7","article-title":"Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study","volume":"9","author":"McCredie","year":"2008","journal-title":"Lancet Oncol"},{"key":"R6-20260825","doi-asserted-by":"crossref","first-page":"101058","DOI":"10.1016\/j.tranon.2021.101058","article-title":"In situ immunopathological events in human cervical intraepithelial neoplasia and cervical cancer: review","volume":"14","author":"Carrero","year":"2021","journal-title":"Transl Oncol"},{"key":"R7-20260825","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ygyno.2020.01.023","article-title":"The risk of cervical cancer after cervical intraepithelial neoplasia grade 3: a population-based cohort study with 80,442 women","volume":"157","author":"Loopik","year":"2020","journal-title":"Gynecol Oncol"},{"key":"R8-20260825","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1067\/mob.2002.118918","article-title":"Factors associated with an increased risk of prevalent and incident grade III cervical intraepithelial neoplasia and invasive cervical cancer among women with Papanicolaou tests classified as grades I or II cervical intraepithelial neoplasia","volume":"186","author":"Petry","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"R9-20260825","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1001\/jama.2023.13174","article-title":"Cervical cancer screening: a review","volume":"330","author":"Perkins","year":"2023","journal-title":"JAMA"},{"key":"R10-20260825","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/00003081-200006000-00018","article-title":"Management of high-grade cervical intraepithelial neoplasia and low-grade squamous intraepithelial lesion and potential complications","volume":"43","author":"Montz","year":"2000","journal-title":"Clin Obstet Gynecol"},{"key":"R11-20260825","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/LGT.0000000000000525","article-title":"2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors","volume":"24","author":"Perkins","year":"2020","journal-title":"J Low Genit Tract Dis"},{"key":"R12-20260825","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001318.pub2","article-title":"Surgery for cervical intraepithelial neoplasia","author":"Martin-Hirsch","year":"2010","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"R13-20260825","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0140-6736(94)90881-8","article-title":"Efficacy and safety of large-loop excision of the transformation zone","volume":"343","author":"Bigrigg","year":"1994","journal-title":"Lancet"},{"key":"R14-20260825","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.21037\/tcr-22-1466","article-title":"Relationship between positive margin and residual\/recurrence after excision of cervical intraepithelial neoplasia: a systematic review and meta-analysis","volume":"11","author":"Feng","year":"2022","journal-title":"Transl Cancer Res"},{"issue":"suppl 5","key":"R15-20260825","doi-asserted-by":"crossref","first-page":"F88","DOI":"10.1016\/j.vaccine.2012.06.095","article-title":"Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer","volume":"30","author":"Arbyn","year":"2012","journal-title":"Vaccine"},{"key":"R16-20260825","doi-asserted-by":"crossref","first-page":"172.e1","DOI":"10.1016\/j.ajog.2019.08.042","article-title":"Incomplete excision of cervical intraepithelial neoplasia as a predictor of the risk of recurrent disease\u2014a 16-year follow-up study","volume":"222","author":"Alder","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"R17-20260825","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1136\/bmj.38663.459039.7C","article-title":"Risk of cervical and other cancers after treatment of cervical intraepithelial neoplasia: retrospective cohort study","volume":"331","author":"Kalliala","year":"2005","journal-title":"BMJ"},{"key":"R18-20260825","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S1470-2045(17)30700-3","article-title":"Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis","volume":"18","author":"Arbyn","year":"2017","journal-title":"Lancet Oncol"},{"key":"R19-20260825","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S1470-2045(07)70283-8","article-title":"Incomplete excision of cervical intraepithelial neoplasia and risk of treatment failure: a meta-analysis","volume":"8","author":"Ghaem-Maghami","year":"2007","journal-title":"Lancet Oncol"},{"key":"R20-20260825","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.ygyno.2005.07.033","article-title":"Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence","volume":"99","author":"Arbyn","year":"2005","journal-title":"Gynecol Oncol"},{"key":"R21-20260825","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2303.2008.00636.x","article-title":"European guidelines for clinical management of abnormal cervical cytology, part 2","volume":"20","author":"Jordan","year":"2009","journal-title":"Cytopathology"},{"key":"R22-20260825","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1470-2045(11)70078-X","article-title":"Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study","volume":"12","author":"Kocken","year":"2011","journal-title":"Lancet Oncol"},{"key":"R23-20260825","doi-asserted-by":"crossref","first-page":"e7186","DOI":"10.1136\/bmj.e7186","article-title":"Follow-up after treatment for cervical intraepithelial neoplasia","volume":"345","author":"Bleeker","year":"2012","journal-title":"BMJ"},{"key":"R24-20260825","doi-asserted-by":"crossref","first-page":"e6855","DOI":"10.1136\/bmj.e6855","article-title":"Risk of cervical cancer after completed post-treatment follow-up of cervical intraepithelial neoplasia: population based cohort study","volume":"345","author":"Rebolj","year":"2012","journal-title":"BMJ"},{"key":"R25-20260825","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"R26-20260825","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"R27-20260825","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/2049-3258-72-39","article-title":"Metaprop: a Stata command to perform meta-analysis of binomial data","volume":"72","author":"Nyaga","year":"2014","journal-title":"Arch Public Health"},{"key":"R28-20260825","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/jrsm.1634","article-title":"Comparison and validation of metadta for meta\u2010analysis of diagnostic test accuracy studies","volume":"14","author":"Nyaga","year":"2023","journal-title":"Res Synth Methods"},{"key":"R29-20260825","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1536867X0800800102","article-title":"Metan: fixed- and random-effects meta-analysis","volume":"8","author":"Harris","year":"2008","journal-title":"Stata J Promot Commun Stat Stata"},{"key":"R30-20260825","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"R31-20260825","first-page":"3733","article-title":"Is therapeutic conization sufficient to eliminate a high-risk HPV infection of the uterine cervix? A clinicopathological analysis","volume":"22","author":"Bodner","year":"2002","journal-title":"Anticancer Res"},{"key":"R32-20260825","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/j.1471-0528.2006.01063.x","article-title":"Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation","volume":"113","author":"Verguts","year":"2006","journal-title":"BJOG"},{"key":"R33-20260825","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ygyno.2006.04.016","article-title":"Pre- and post-conization high-risk HPV testing predicts residual\/recurrent disease in patients treated for CIN 2-3","volume":"103","author":"Alonso","year":"2006","journal-title":"Gynecol Oncol"},{"key":"R34-20260825","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.ajog.2003.09.054","article-title":"Usefulness of human papillomavirus testing in the follow-up of patients with high-grade cervical intraepithelial neoplasia after conization","volume":"190","author":"Chao","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"R35-20260825","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1054\/bjoc.2000.1689","article-title":"Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia","volume":"84","author":"Nobbenhuis","year":"2001","journal-title":"Br J Cancer"},{"key":"R36-20260825","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0090-8258(03)00435-9","article-title":"Follow-up by combined cytology and human papillomavirus testing for patients post-cone biopsy: results of a long-term follow-up","volume":"91","author":"Bar-Am","year":"2003","journal-title":"Gynecol Oncol"},{"key":"R37-20260825","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0090-8258(03)00415-3","article-title":"HPV testing can reduce the number of follow-up visits in women treated for cervical intraepithelial neoplasia grade 3","volume":"91","author":"Zielinski","year":"2003","journal-title":"Gynecol Oncol"},{"key":"R38-20260825","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/030089160409000211","article-title":"Persistent human papilloma virus infection as an indicator of risk of recurrence of high-grade cervical intraepithelial neoplasia treated by the loop electrosurgical excision procedure","volume":"90","author":"Cecchini","year":"2004","journal-title":"Tumori"},{"key":"R39-20260825","first-page":"589","article-title":"Human papillomavirus DNA status after loop excision for cervical intraepithelial neoplasia grade III\u2014a prospective study","volume":"13","author":"Nagai","year":"2004","journal-title":"Int J Mol Med"},{"key":"R40-20260825","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ygyno.2004.03.036","article-title":"HPV DNA test and pap smear in detection of residual and recurrent disease following loop electrosurgical excision procedure of high-grade cervical intraepithelial neoplasia","volume":"94","author":"Sarian","year":"2004","journal-title":"Gynecol Oncol"},{"key":"R41-20260825","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ygyno.2007.12.032","article-title":"PCR detection rates of high risk human papillomavirus DNA in paired self-collected urine and cervical scrapes after laser CO2 conization for high-grade cervical intraepithelial neoplasia","volume":"109","author":"Fambrini","year":"2008","journal-title":"Gynecol Oncol"},{"key":"R42-20260825","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2303.2008.00567.x","article-title":"Prediction of recurrent disease by cytology and HPV testing after treatment of cervical intraepithelial neoplasia","volume":"20","author":"Aerssens","year":"2009","journal-title":"Cytopathology"},{"key":"R43-20260825","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/ijc.23824","article-title":"Post-treatment CIN: randomised clinical trial using hrHPV testing for prediction of residual\/recurrent disease","volume":"124","author":"Bais","year":"2009","journal-title":"Int J Cancer"},{"key":"R44-20260825","doi-asserted-by":"crossref","first-page":"17.e1","DOI":"10.1016\/j.ajog.2009.01.005","article-title":"Follow-up after treatment of cervical intraepithelial neoplasia by human papillomavirus genotyping","volume":"201","author":"Brismar","year":"2009","journal-title":"Am J Obstet Gynecol"},{"key":"R45-20260825","doi-asserted-by":"crossref","first-page":"72.e1","DOI":"10.1016\/j.ajog.2010.01.063","article-title":"Significance of human papillomavirus genotyping with high-grade cervical intraepithelial neoplasia treated by a loop electrosurgical excision procedure","volume":"203","author":"Kang","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"R46-20260825","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1479-828X.2009.01132.x","article-title":"Testing for high risk human papilloma virus in the initial follow-up of women treated for high-grade squamous intraepithelial lesions","volume":"50","author":"Smart","year":"2010","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"R47-20260825","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ygyno.2011.07.032","article-title":"Role of high-risk human papillomavirus (HPV) mRNA testing in the prediction of residual disease after conisation for high-grade cervical intraepithelial neoplasia","volume":"123","author":"Trop\u00e9","year":"2011","journal-title":"Gynecol Oncol"},{"key":"R48-20260825","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3802\/jgo.2012.23.4.217","article-title":"Early human papillomavirus testing predicts residual\/recurrent disease after LEEP","volume":"23","author":"Ryu","year":"2012","journal-title":"J Gynecol Oncol"},{"key":"R49-20260825","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/1471-0528.12072","article-title":"Intraoperative post-conisation human papillomavirus testing for early detection of treatment failure in patients with cervical intraepithelial neoplasia: a pilot study","volume":"120","author":"Torn\u00e9","year":"2013","journal-title":"BJOG"},{"key":"R50-20260825","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ygyno.2014.09.022","article-title":"Value of endocervical margin and high-risk human papillomavirus status after conization for high-grade cervical intraepithelial neoplasia, adenocarcinoma in situ, and microinvasive carcinoma of the uterine cervix","volume":"135","author":"Kong","year":"2014","journal-title":"Gynecol Oncol"},{"key":"R51-20260825","doi-asserted-by":"crossref","first-page":"8063","DOI":"10.7314\/APJCP.2014.15.19.8063","article-title":"Role of the HPV DNA test in follow-up of treated cervical intraepithelial neoplasia in Bangladesh","volume":"15","author":"Nessa","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"R52-20260825","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jasc.2013.09.004","article-title":"Human papillomavirus testing and cytologic\/histopathologic \u201ctest of cure\u201d follow-up results after excisional treatment for high-grade cervical intraepithelial neoplasia","volume":"3","author":"Zhao","year":"2014","journal-title":"J Am Soc Cytopathol"},{"key":"R53-20260825","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/aogs.12601","article-title":"Role of human papillomavirus testing and cytology in follow-up after conization","volume":"94","author":"Gosvig","year":"2015","journal-title":"Acta Obstet Gynecol Scand"},{"key":"R54-20260825","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/ijc.28978","article-title":"Unique recurrence patterns of cervical intraepithelial neoplasia after excision of the squamocolumnar junction","volume":"136","author":"Herfs","year":"2015","journal-title":"Int J Cancer"},{"key":"R55-20260825","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/GME.0000000000000488","article-title":"Human papillomavirus genotyping as a reliable prognostic marker of recurrence after loop electrosurgical excision procedure for high-grade cervical intraepithelial neoplasia (CIN2-3) especially in postmenopausal women","volume":"23","author":"Kang","year":"2016","journal-title":"Menopause"},{"key":"R56-20260825","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1159\/000437423","article-title":"Analysis of residual\/recurrent disease and its risk factors after loop electrosurgical excision procedure for high-grade cervical intraepithelial neoplasia","volume":"81","author":"Wu","year":"2016","journal-title":"Gynecol Obstet Invest"},{"key":"R57-20260825","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/ijc.25745","article-title":"Type-specific HPV geno-typing improves detection of recurrent high-grade cervical neoplasia after conisation","volume":"129","author":"Heymans","year":"2011","journal-title":"Int J Cancer"},{"key":"R58-20260825","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1006\/gyno.1997.4753","article-title":"Human papillomavirus analysis as a prognostic marker following conization of the cervix uteri","volume":"66","author":"Chua","year":"1997","journal-title":"Gynecol Oncol"},{"key":"R59-20260825","first-page":"833","article-title":"Human papillomavirus testing and the outcome of treatment for cervical intraepithelial neoplasia","volume":"98","author":"Paraskevaidis","year":"2001","journal-title":"Obst Gynecol"},{"key":"R60-20260825","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1471-0528.2002.01554.x","article-title":"Persistent infection with human papillomavirus following the successful treatment of high grade cervical intraepithelial neoplasia","volume":"109","author":"Cruickshank","year":"2002","journal-title":"BJOG"},{"key":"R61-20260825","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ejogrb.2016.12.018","article-title":"HPV-based strategy in follow-up of patients treated for high-grade cervical intra-epithelial neoplasia: 5-year results in a public health surveillance setting","volume":"210","author":"Garutti","year":"2017","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R62-20260825","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/aogs.13325","article-title":"HPV-testing versus HPV-cytology co-testing to predict the outcome after conization","volume":"97","author":"Bruhn","year":"2018","journal-title":"Acta Obstet Gynecol Scand"},{"key":"R63-20260825","doi-asserted-by":"crossref","first-page":"e13606","DOI":"10.1097\/MD.0000000000013606","article-title":"Persistent HPV-16 infection leads to recurrence of high-grade cervical intraepithelial neoplasia","volume":"97","author":"Byun","year":"2018","journal-title":"Medicine"},{"key":"R64-20260825","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12985-019-1252-3","article-title":"HPV16 persistent infection and recurrent disease after LEEP","volume":"16","author":"Bruno","year":"2019","journal-title":"Virol J"},{"key":"R65-20260825","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/1471-0528.15996","article-title":"Long\u2010term predictors of residual or recurrent cervical intraepithelial neoplasia 2\u20133 after treatment with a large loop excision of the transformation zone: a retrospective study","volume":"127","author":"Fern\u00e1ndez-Montol\u00ed","year":"2020","journal-title":"BJOG"},{"key":"R66-20260825","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.3802\/jgo.2020.31.e60","article-title":"Age-specific predictors of cervical dysplasia recurrence after primary conization: analysis of 3,212 women","volume":"31","author":"Bogani","year":"2020","journal-title":"J Gynecol Oncol"},{"key":"R67-20260825","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ygyno.2020.06.490","article-title":"Value of endocervical curettage in follow-up for patients with cervical intraepithelial neoplasia stage 2+ after loop electrosurgical excision","volume":"158","author":"Cao","year":"2020","journal-title":"Gynecol Oncol"},{"key":"R68-20260825","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.3390\/cancers12061683","article-title":"Role of colposcopy after treatment for cervical intraepithelial neoplasia","volume":"12","author":"Heinonen","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R69-20260825","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.2147\/CMAR.S237490","article-title":"Evaluation of PCR-reverse dot blot human papillomavirus genotyping test in predicting residual\/recurrent CIN 2+ in posttreatment patients in China","volume":"12","author":"Zhang","year":"2020","journal-title":"Cancer Manag Res"},{"key":"R70-20260825","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.3390\/cancers13133309","article-title":"Evaluation of integrated HPV DNA as individualized biomarkers for the detection of recurrent CIN2\/3 during post-treatment surveillance","volume":"13","author":"Hoyer","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R71-20260825","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.3390\/cancers13153664","article-title":"Human papillomavirus same genotype persistence and risk of cervical intraepithelial neoplasia2+ recurrence","volume":"13","author":"Iacobone","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R72-20260825","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/ijgo.14340","article-title":"Risk factors analysis of recurrent disease after treatment with a loop electrosurgical excision procedure for high-grade cervical intraepithelial neoplasia","volume":"160","author":"Ding","year":"2023","journal-title":"Int J Gynaecol Obstet"},{"key":"R73-20260825","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s12957-023-03088-5","article-title":"Analysis of outcomes following loop electrosurgical excision and clinical features of patients with cervical high-grade squamous intraepithelial lesions with abnormal preoperative endocervical curettage","volume":"21","author":"Feng","year":"2023","journal-title":"World J Surg Oncol"},{"key":"R74-20260825","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/LGT.0000000000000803","article-title":"Performance of different follow-up strategies and genotype-based recurrence risk after treatment of cervical high-grade squamous intraepithelial lesion","volume":"28","author":"Gra\u00e7a","year":"2024","journal-title":"J Low Genit Tract Dis"},{"key":"R75-20260825","doi-asserted-by":"crossref","first-page":"118","DOI":"10.7326\/M15-2735","article-title":"Genotyping for human papillomavirus types 16 and 18 in women with minor cervical lesions: a systematic review and meta-analysis","volume":"166","author":"Arbyn","year":"2017","journal-title":"Ann Intern Med"},{"key":"R76-20260825","first-page":"1458","article-title":"The mRNA-HPV test utilization in the follow up of HPV related cervical lesions","volume":"19","author":"Tinelli","year":"2013","journal-title":"Curr Pharm Des"},{"key":"R77-20260825","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/ijc.30449","article-title":"Good performance of p16\/ki-67 dual-stained cytology for surveillance of women treated for high-grade CIN","volume":"140","author":"Polman","year":"2017","journal-title":"Int J Cancer"},{"key":"R78-20260825","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ygyno.2016.07.089","article-title":"Performance of CADM1\/MAL-methylation analysis for monitoring of women treated for high-grade CIN","volume":"143","author":"Uijterwaal","year":"2016","journal-title":"Gynecol Oncol"},{"key":"R79-20260825","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1158\/1078-0432.CCR-17-3251","article-title":"Human papillomavirus DNA methylation as a biomarker for cervical precancer: consistency across 12 genotypes and potential impact on management of HPV-positive women","volume":"24","author":"Clarke","year":"2018","journal-title":"Clin Cancer Res"},{"key":"R80-20260825","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/jmv.25208","article-title":"Factors affecting residual\/recurrent cervical intraepithelial neoplasia after cervical conization with negative margins","volume":"90","author":"Fan","year":"2018","journal-title":"J Med Virol"},{"key":"R81-20260825","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ygyno.2006.10.011","article-title":"HPV16 and increased risk of recurrence after treatment for CIN","volume":"104","author":"G\u00f6k","year":"2007","journal-title":"Gynecol Oncol"},{"key":"R82-20260825","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1158\/1055-9965.EPI-05-0845","article-title":"Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease","volume":"15","author":"Kreimer","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005997","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:00:36Z","timestamp":1787652036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005997"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":82,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000005997","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"2025-02-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}